Company / Financials
Regeneron Pharmaceuticals Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$14.3B
FY2025 · +1.0% YoY
Net Income
$4.5B
FY2025 · +2.1% YoY
Profit Margin
31.4%
FY2025 · net income / revenue
ROE
14.4%
FY2025 · return on equity
Total Assets
$40.6B
FY2025
Total Debt
$2.0B
0.06x debt/equity
Equity
$31.3B
FY2025
ROA
11.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$14.3B+1.0% YoYNet Income HistoryProfit after all expenses and taxes$4.5B+2.1% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$237.5MOperating Income HistoryProfit from core business operations before interest and taxes$3.6B-10.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$2.7B-8.6% YoYR&D Expense HistoryResearch and development spending$5.9B+14.0% YoYInterest Expense HistoryCost of borrowing and debt obligations$73.0MIncome Tax HistoryTotal income tax expense$725.8M+97.6% YoYEPS (Basic) HistoryBasic earnings per share$37.05-8.5% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles$34.77-9.0% YoY